

Information and Networking Event Horizon Europe 2023 Calls Co-Funded by the Government of India (DBT)



HORIZON-HLTH-2024-DISEASE-08-20: Pandemic preparedness and response: Host-pathogen interactions of infectious diseases with epidemic potential Friday, 13 October 2023

- TITLE of talk: Host-targeted therapeutics for infectious diseases with epidemic potential.
- Name of Presenter: Prof. Amit Awasthi
- Name of contributors: Dr. Supratik Das, Dr. Zaigham Abbas Rizvi, Dr. Tanvi Agarwal
- Name of Organisation: Translational Health Science & Technology Institute (THSTI)
- Country: India
- Your contact details: Email: <u>aawasthi@thsti.res.in</u>
- Your web url: <u>https://thsti.res.in/en/faculty-profile/Amit-Awasthi</u>

Project Overall

Title: Host-targeted therapeutics for infectious diseases with epidemic potential.

Objectives:

- 1. Characterization of host-factor driving the entry, replication and pathogenesis of DENV and CHIKV infection.
- 2. Integrated approaches for improved host-directed therapy and adjuvants.
- 3. Advanced pre-clinical platform for *in-vitro* and *in-vivo* validation.

Project Coordinator: Prof. Amit Awasthi

PI: Prof. Amit Awasthi, Dr. Supratik Das, Dr. Zaigham Abbas Rizvi, Dr. Tanvi Agarwal




Project 1

Title: Development and validation of novel host-directed therapy.

Objectives:

- 1. Screening, identification and characterization of novel host-directed therapy for CHIKV and DENV infection.
- 2. Next-gen adjuvants for existing vaccine candidates.





Amit Awasthi

Project 2


Title: Establishment of advanced pre-clinical animal platform for CHIKV and DENV infection for translational research.

Objectives:

a. Humanized mice model for host-pathogen interaction.



b. Development and harmonization of human Immune organoid system.




Amit Awasthi & Zaigham Abbas Rizvi

Vaccine Candidates and Host-Pathogen Interaction in DENV/CHIKV

- A) To provide protein-based platform for subunit vaccine immunogen design for infectious diseases.
- B) Understand host-pathogen interaction in order to identify drug targets.








Dengue

CHIKV



Supratik Das

Background: CHIKV and DENV envelope protein spike is the sole target of desirable neutralizing antibodies.




Aim: To prepare CHIKV-sE1-sE2-E3 protein trimer and DENV1-4 sE dimer for use as a vaccine candidate.

Results:

- Purified CHIKV sE1-sE2-E3 protein trimer to apparent homogeneity.
- Purified DENV3, DENV4 sE dimers to apparent homogeneity.
- Biochemical and antigenic characterization of CHIKV trimer and DENV3, DENV4 dimers completed.
- Structural characterization ongoing.
- Immunogenicity studies of CHIKV sE1-sE2-E3 timer in mice completed. Potent humoral and cell mediated immunity obtained.
- Purification and characterization of DENV1, DENV2 sE dimers ongoing.

Identifying Dengue virus (DENV) Structural Protein Interacting Host-Proteins

<u>Background:</u> DENV non-capsid structural protein interacting host proteins are not known. These interactions may be potent targets for therapeutic intervention.



Aim: To identify and characterize DENV non-capsid structural protein interacting host proteins.

Results:

Initial constructs have been generated and characterized.



Identification and characterization of host receptors for Chikungunya virus for targeted drug designing

A) To identify and characterise host cell receptors interacting with envelope or capsid protein of Chikungunya virus.

B) To design and validate drug against identified host receptors.

Background:

Host receptors involved in entry of Chikungunya virus and not clearly defined. As no antiviral is available for Chikungunya identification and characterization of these receptors can serve as targets for designing better antiviral strategy.

Work Plan:

- 1. To identify and characterise host cell receptors interacting with envelope or capsid protein of Chikungunya virus.
 - a) Identification of host receptors Tagged construct of structural proteins will be used to pull interacting proteins which are identified by Mass Spectrometry.
 - b) Identified receptors will be characterised across a repertoire of cells through either loss of function or blockage of receptors.
- 2 To design and validate drug(s) against identified host receptors both in vivo and in vitro.



Tanvi Agarwal

Available Infrastructure/Facility



Small Animal Facility



Established in 2013 at NCR-Biotech Science Cluster, CPSEA accredited (1685/GO/REBI/S/2013/CPCSEA)

Capac	city			
Mice •15 IVCs •2736 Cages •8000-13000 Mice	Rats •3 IVCs •390 Cages •1000-1500 Rats	29 Mutant mi	3 Inbred mice strains29 Mutant mice strains1 Hybrid mice strain	
AND	AR SEPTER		Estab	
ITAC & BUS		PTOCLASES	S	

Infectious Disease Research Facility



Established in 2018 at NCR-Biotech Science Cluster, RCGM accredited

SARS-CoV2 in vitro and in vivo research Mycobacterium tuberculosis research HIV research

Immunology Core LAB

New Bsl3 facility has been commissioned and functional.




Othsti

Established in 2020 at THSTI

Infectious disease research SARS-CoV2 pre-clinical and clinical trials

Capacity in Vaccine Research








Amit Awasthi

INFLUENZA VIRUS REASERCH

MANDATE

A translational research platform to accelerate the development of broadly effective and low-cost Influenza vaccines and therapeutics







thsti

What we are looking for in collaborators.

- a) We are looking for collaborators who have existing or are developing or are interested in developing non-mice animal models (including non-human primates) which can be used to test CHIKV and DENV vaccine candidates.
- b) We are looking for collaborators who are interested in dynamics of host receptor ligand interaction.
- c) Potential collaborators to take PoC drug and vaccine targets for NHP trials.
- d) Potential collaborators who are interested in pre-clinical trials of putative drug candidates.



Golden Syrian Hamster



Ferret



Rhesus Macaque

Industrial Partner



